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Somatic mutations of the Estrogen Receptor α (ERα) occur with an up to 40% incidence in ER sensitive 
breast cancer (BC) patients undergoing prolonged endocrine treatments. These polymorphisms are 
implicated in acquired resistance, disease relapse, and increased mortality rates, hence representing 
a current major clinical challenge. Here, multi-microseconds (12.5 µs) molecular dynamics simulations 
revealed that recurrent ERα polymorphisms (i. e. L536Q, Y537S, Y537N, D538G) (mERα) are 
constitutively active in their apo form and that they prompt the selection of an agonist (active)-like 
conformation even upon antagonists binding. Interestingly, our simulations rationalize, for the first 
time, the efficacy profile of (pre)clinically used Selective Estrogen Receptor Modulators/Downregulators 
(SERMs/SERDs) against these variants, enlightening, at atomistic level of detail, the key common 
structural traits needed by drugs able to effectively fight refractory BC types. This knowledge represents 
a key advancement for mechanism-based therapeutics targeting resistant ERα isoforms, potentially 
allowing the community to move a step closer to ‘precision medicine’ calibrated on patients’ genetic 
profiles and disease progression.
Breast Cancer (BC) is the most frequent cancer type as well as the second leading cause of death in women. 
Approximately 70% of BC cases, detected after menopause, express Estrogen Receptor (ER) and are classified 
as ER sensitive (ER+)1. After the menopause, estrogens (17-β-estradiol or estrone) are primarily produced by 
human aromatase (HA) enzyme, whose deregulated activity leads to increased estrogens levels in malignant tis-
sues1–5. These hormones bind as agonist to ERα, which, then, exerts a pro-oncogenic effect by either decreasing 
apoptosis or promoting cell proliferation1. So far, endocrine treatments of ER + BC rely on estrogens deprivation, 
by inhibiting HA, or on small molecule regulators of ERα, such as selective ERα modulators (SERMs) or down-
regulators (SERDs). The latter, besides being ERα antagonists, occupies the substrate binding site and induces a 
conformational change in the receptor, as SERMs do, also prompt ERα ubiquitination and degradation6.
ERα is a nuclear hormone receptor and a ligand-regulated transcription factor, mediating the activity of estro-
gens in many important physiological processes (i. e. reproduction, cardiovascular maintenance, bone density/
remodelling)7,8. ERα is composed by five distinct functional domains (Figure (Fig.) S1 of the Supplementary 
Information (SI)), among which only the structures of the DNA-binding domain and the ligand-binding domain 
(LBD) have been determined crystallographically. At physiological conditions ERα exists as a dimer, stabilized by 
the binding of either agonists or antagonists. The crystal structures have revealed that the most important struc-
tural element of each LBD monomer (Fig. 1) is helix 12 (H12), which acts as a molecular switch between the active 
and inactive conformation of the receptor9. Indeed, upon estrogen binding, H12 occludes the ligand-binding site, 
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packing against helixes H3, H5/6, and H11 (Fig. 1a)10. This corresponds to the agonist (active) conformation of 
ERα. In contrast, when an antagonist binds, it prevents H12 from assuming the agonist conformation, and H12 
moves towards a groove formed by H3 and H510. This corresponds to the antagonist (inactive) conformation of 
ERα (Fig. 1b)11.
The most effective ERα antagonists in current clinical use are (Fig. 2): (i) tamoxifen, a SERM, which is active 
through its metabolites, but it is endowed with agonist effects in peripheral tissues; and (ii) fulvestrant, a SERD 
downregulating ERα, with no agonist effects8,12, which suffers, however, from poor pharmacokinetic properties 
(e. g. low solubility in water).
The clinical use of tamoxifen has been extremely beneficial for BC patients in the last decades, reducing BC 
mortality rates by 25–30%. However, up to 40% of all ER+ BC patients, initially responding to the endocrine 
treatments, acquire resistance during disease progress and frequently relapse after prolonged therapies. Recent 
studies by Robinson et al.13, Toy et al.14, Merenbakh-Lamin et al.15, and Jeselsohn et al.16 pinpointed several ERα 
Figure 1. ERα LBD monomer in agonist (a) and antagonist conformation (b), with secondary structure 
elements coloured in distinct colours. The helices label comprises both residues forming helices and those 
located on the loops connecting them. Namely, H1: residues 303–311 (red); H2: residues 312–322 (dark 
orange); coil2–3 (C2–3): residues 323–338 (orange); H3: residues 339–363 (yellow); H4: residues 364–371 (light 
green); H5: residues 372–382 (dark green); H6: residues 383–396 (turquoise); S1, S2: residues 397–411 (dark 
turquoise); H7: residues 412–419 (dark blue); H8: residues 420–439 (light blue); H9: residues 440–463 (blue); 
H10: residues 464–494 (violet); H11: residues 495–531 (pink and grey; coloured in grey are residues 527–531); 
H12: residues 532–552 (magenta).
Figure 2. Chemical structures of 17-β-estradiol (1), tamoxifen (2), endoxifen (3), AZD-9496 (4), fulvestrant 
(5), and GDC-0810 (6).
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polymorphisms (mERαs) located in the LBD, either in the vicinity of the estrogens binding site (i. e. E380Q), 
between H9 and H10 (S463P) or, more frequently, in the loop connecting H11 and H12 (i. e. L536Q, L536R, 
Y537C, Y537N, Y537S, and D538G). These occur at high rate in relapsed metastatic patients, while being rare or 
absent in primary tumours of untreated patients13,14,16. Independent studies unambiguously demonstrated that 
these mERαs contributed to the acquired resistance to endocrine treatments1, indicating that BC evolves new 
traits to escape the pressure of currently used therapeutics. The reported frequencies of specific ERα polymor-
phisms differ according to the clinical study. Namely, the D538G was present in 21–36% of cases16–18, Y537N in 
5–33%16,18, and Y537S in 13–22%16–18, while the other polymorphisms are less frequent14,18. In few cases a double 
D538G and Y537S mutant was also observed14,17. The abundance of these mutations is not directly correlated to 
the overall survival time of patients (D538G 26 months, Y537S 20 months, and 15 months for double mutant 
Y537S and D538G)17, with Y537S being the most aggressive isoform.
Since these polymorphisms are highly recurrent, endocrine resistance in BC is becoming a major clinical prob-
lem. Cell lines expressing ERα mutations are insensitive to HA inhibitors, but remain partially sensitive to high 
doses of current anti-estrogen therapies (i. e. endoxifen/tamoxifen, fulvestrant), enlightening that ERα-mediated 
signalling remains important even in advanced metastatic BCs refractory to therapies. Experimental studies, 
aimed at developing novel SERDs, led to the discovery of AZD-949619 and GDC-08107, currently in phase I and 
II of clinical trials, respectively, for the treatment of advanced ER+ BC (Fig. 2). Importantly, these drugs partially 
retain their efficacy even in the resistant cell lines.
Despite the clinical incidence of the problem, at this point, no clear molecular picture for the structural mech-
anisms underlying the emergence of resistance in ER exists, nor for the improved efficacy profile of the novel 
generation of SERDs against these aggressive variants.
Even though the multifactorial nature of cancer as a disease, in which many different players concur to deter-
mine the positive vs. negative response to drugs, our aim here is to address a specific set of molecular properties 
linked to resistance BC manifestations and rationalize how to overcome this. Atomistic simulations have the 
potential to clarify such mechanisms and rationalize the efficacy profile of current drugs in specific polymor-
phisms at the microscopic level, offering a spatial (atomistic) and temporal (ns) resolution inaccessible, yet com-
plementary, to experimental methods2,20. Computational studies aimed at clarifying the mechanism of mERαs 
have so far been limited to the most frequent Y537S and D538G isoforms11,14,18,21–23. They enlightened that these 
mutants are constitutively active, but with a distinct molecular mechanism15,22,23. The other mutants, not yet stud-
ied, may also have different activation pathway leading to mutant-dependent responses to therapies23.
Here we performed force field-based molecular dynamics (MD) simulations, for a cumulative time of 12.5 µs, 
on wild type (WT) ERα and four selected mERα variants (L536Q, Y537S, Y537N, and D538G) aiming at (i) clar-
ifying how the complex conformational landscape of these ERα isomorphisms induces estrogen (EST) (hereafter 
EST refers to 17-β-estradiol) independent ERα activation; and (ii) elucidating which are the key structural sig-
natures that render new-generation hormonal therapies (fulvestrant and AZD-9496) effective on these polymor-
phisms. This complete and detailed investigation represents a step forward towards precision medicine against 
refractory BC types. Indeed, although ESR1 mutations are not yet a validated clinical biomarker, they are being 
currently evaluated as a potential biomarker to guide therapeutic decisions. Thus, targeted therapy directed to the 
ESR1 mutants is a subject of intense preclinical and early clinical work24.
Results and Discussion
Since a complete structure of the ERα is not available, in this work, we focused on the LBD dimer, as in other 
computational studies14,22,25. For the agonist conformation, we considered the apo and EST-bound form of WT 
ERα and four recurrent mERαs (L536Q, Y537S, Y537N, D538G), localized on the loop L11–12, connecting H11 
and H12, and endoxifen-, AZD-9496-, and fulvestrant-bound WT ERα and the same four mERαs for the antag-
onist conformation. For all systems, we performed 500 ns of MD simulations, although convergence was reached 
after 200 ns (Fig.s S2 and S3). A discussion of the per-residue RMSF is detailed in the SI (Paragraph S1, Fig.s S4 
and S5, respectively).
To verify our results, we compared structures of the highest populated cluster (see Table 1 of SI (Table S1)) 
of complexes obtained from our simulations with available crystal structures. For the EST-bound complexes 
this was possible only for WT26 and Y537S27 mutant and in both cases comparison revealed no major structural 
differences. Additionally, clusters’ population analysis showed that both EST-bound and apo ERα, in all polymor-
phisms studied (WT and mERαs), are quite rigid.
Since our simulations refer to two different conformational states of ERα (i. e. open (antagonist) and 
closed (agonist)) and our simulations’ time-scale (500 ns per system) does not allow to directly observe their 
inter-conversion, we will analyse the two states separately. In the following paragraphs we will look for a met-
ric allowing us to classify the preferred conformational state of H12, the key structural element of ERα signal 
transmission.
Agonist conformation. To identify signatures and metric of ERα activation we have initially compared the 
cross-correlation matrices of apo and EST-bound WT (WT/EST) agonist conformations (Fig.s 3 and S6). These 
reveal a correlation contact between H12 and H3 in the EST/WT adduct (the active form of the receptor), which 
is not present in apo form (the inactive state). Thus, we consider this correlation contact as the signature of ERα 
activation. Remarkably, the same correlation contact is also present in all mutant apo ERα isoforms, highlighting 
their constitutively active character. This is in line with experimental findings suggesting that ERα polymor-
phisms are intrinsically active even in the absence of EST and explains why metastatic BC types developing these 
ERα isoforms are insensitive to HA inhibitors.
Moreover, in the WT/EST a second contact is present between H7 and H3. This contact occurs only in the 
apo and EST bound forms of L536Q and D538G (hereafter L536Q/EST and D538G/EST), pinpointing a different 
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activation mechanism with respect to the other two mutants. A clear anti-correlation between the two LBD mon-
omers observed only in the apo L536Q and D538G (Figs 3 and S6) further confirms this. The presence of these 
mutants appears to reduce the symmetry of the two monomers, although we cannot exclude that this may be 
caused by a structural perturbation induced by the mutant, which is not recovered in our simulation time scale. 
Figure 3. Cross-correlation maps of 14 regions (as defined in Fig. 1) of both, apo monomers of WT and the 
selected mERαs, and WT/EST. The cross-correlation coefficients, calculated as the sum of the cross-correlation 
coefficients (with a correlation score ≥ or ≤ than 0.6 and −0.6) of the residues belonging to two regions 
considered (see Paragraph S2 for details). Cross-correlation scores are reported in the range from −0.3 to 0.3 for 
clarity reasons. Blue and red colours account for positive and negative correlation, respectively.
www.nature.com/scientificreports/
5SCieNtifiC REPORTS |  (2018) 8:649  | DOI:10.1038/s41598-017-17364-4
Estrogen binding to mERαs reduces the observed anti-correlation between monomers and re-establishes the 
same correlation contacts of WT/EST (Fig. S6).
Figure 4, displaying the correlation of H12 with the rest of the protein, gives a more semi-quantitative picture 
of the relative degree of activation of different isoforms, as emerging from our simulations. As such, we use the 
relative correlation score as a metric to discriminate between the ERα active and inactive states. Namely, the 
active EST/WT adduct has a correlation score of 4 between H12 and H3, which we take as a reference value for 
activation. Importantly, this plot enlightens that H12 correlates with H3 in all mutants, although with a lower 
score than the EST/WT adduct.
Figure 4. Sum of per-residue cross-correlation coefficients of H12 for the H12 residues with the rest of the 
LBD. Left and right columns refer to monomers A and B, respectively. From top to bottom: WT, L536Q, D538G, 
Y537S, and Y537N ERα isoforms are shown. Systems in the apo and estrogen-bound agonist forms are in 
magenta and black, respectively. Systems in the antagonist forms in complex with endoxifen, AZD-9496 and 
fulvestrant are shown as red, green, and blue lines, respectively.
www.nature.com/scientificreports/
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The second largest score, after EST/WT, is recorded for the apo L536Q and Y537S isoforms (both between 
2 and 4), consistently with the fact that the latter is experimentally classified as the most aggressive variant. 
Conversely, the apo Y537N and D538G isoforms have a more limited intrinsic activation. From this graph it is 
also strikingly clear that all mutants are rather insensitive to the presence of EST.
Complementary analyses enlighten a mutant-dependent activation mechanism of ERα, with L536Q and 
D538G having a distinct activation procedure than Y537S and Y537N. Namely, the first two isoforms decrease 
the helical content of the H11/H12 segment, as previously suggested for D538G22,28 (Fig. S7), destabilizing the 
apo state. Instead, Y537S and Y537N induce the formation of hydrogen bonds (H-bonds) between H3 and L11-
12 (i. e. O@L536···H2-Nδ2@N348, Oδ1/Oδ2@D351···H-N@D538, Oδ1/Oδ2@D351···H-N@L539, and Oδ1/Oδ2@
D351···H-N@L540). Moreover, in Y537S there is an additional H-bond formed by the mutant side chain (Oδ1/
Oδ2@D351···H-Oγ@S537), which further stabilizes the L11-12 (Fig. S8, Table S2).
Antagonist conformation. Wild type ERα. We have considered here endoxifen (END) as traditional 
SERM, since this is the most abundant blood circulating metabolite of tamoxifen. When END binds to the WT 
ERα, monomers A and B display different correlation maps (Fig. S9), with H12 being weakly correlated with H3 
and H5 in monomer A, and only with H5 in monomer B. These contacts, although weaker, are still present upon 
AZD-9496 and FULV binding. In all simulations, monomer A appears to be more sensitive than B to the presence 
of the antagonists, as shown by the analysis of the cross-correlation maps (Fig.s S9–13) (vide infra).
We exploit again the overall correlation of H12 with the rest of the protein as a metric of ERα activation. By 
this analysis emerges that when END binds to WT, H12 gains a correlation score of 4 with H3 and H5 in both 
monomers (Fig. 4). This may be consistent with the fact that END modulates the action of ERα, without com-
pletely inactivating it. Since, after many years of clinical use, it is clear that END beneficially antagonizes WT 
ERα, we take this correlation score as a threshold to assess whether a drug is effective/ineffective on the specific 
polymorphism investigated.
By comparing WT in complex with the different antagonists, one can see that in END/WT E380 H-bonds 
to the nearby H377 and that Y537 establishes π-stacking interactions with H377 (Fig.s 5, S14 and S15). In 
contrast, the persistence of this H-bond is slightly reduced and lost in the presence of FULV and AZD-9496 
(Fig. 5, Table S3), respectively. This structural feature is, however, replaced by direct H-bonds between AZD-
9496@O···H3Nζ@K529 and L346@O···H-N@AZD9496 (Fig.s S14, Table S4 and S5). FULV, instead, H-bonds with 
the ligand-binding pocket, similarly to END, and additionally establishes hydrophobic interactions with L11-12 
(Tables S4 and S5, Fig. S14). Indeed, when FULV binds to WT ERα its long tail penetrates in the hydrophobic 
pocket formed by L536, W383, L539, and L540, interacting with L536 (Figs 5 and S13).
The L356Q Isoform. In the END and FULV/L356Q adducts H12 still correlates with H5 in one monomer, while 
this correlation almost vanishes upon AZD-9496-binding (Fig. S10). As mentioned above, the main effect of this 
isoform is mostly to induce disorder in H11, H12, and L11-12, by decreasing the helical content. This is confirmed 
by a decrease of the backbone H-bonds persistence between L536 and L540 in the presence of END, while both 
AZD-9496 and FULV partially recover them (Table S3).
Since the H-bond between the E380 and H377 side chains stabilizes the ERα-antagonist conformation, we 
take its absence as a signature of ERα (partial) activation. Consistently with this hypothesis, the E380Y mutation 
was among the first aggressive ERα variants identified, highlighting the importance of this H-bond for proper 
receptor function. For this reason, in the following discussion, we will monitor the presence/absence of the 
H-bond between E380 and H377 as a structural trait to rationalize the efficacy profiles of the drugs computation-
ally assayed here. In L536Q/END this H-bond is present in both monomers, with its persistence even increasing 
in the presence of AZD-9406 and FULV (Fig. 5, Table S3).
In all L536Q ERα adducts the hydrophobic packing around residue 536 observed in the WT is disrupted by 
the introduction of the polar glutamine side chain. As a result, the secondary structure of H12 is distorted, and 
the π-π interaction between Y537 and H377 is lost in the END-bound complex, while FULV- and AZD-9496 
partially and fully conserve it, respectively (Fig. S15). Again, in this polymorphism FULV penetrates deeply inside 
the hydrophobic pocket and establishes the largest non-bonded interactions with L11-12 and H12 (Table S6 and 
Fig. S14). Additionally, from the clustering analysis (Table S1) one can see that the antagonist conformation of 
the receptor is stabilized/rigidified the most by AZD-9496 followed by FULV. In constrast, a lower stability/larger 
flexibility of the structure is observed in the presence of END, where the highest populated cluster accounts for 
only 57% and 70% of all structures in monomer A and B, respectively.
D538G Isoform. Intriguingly, when END and AZD-9496 bind to D538G, a weak H12-H5 correlation is visible 
in monomer B, while upon FULV binding this becomes stronger in both monomers, but still below the aggressive 
activation threshold (Fig. S11). E380 H-bonds with H377, with a reduced persistence in the END-bound complex 
and with a conserved or increased persistence, with respect to the reference antagonist WT/END form, in the 
presence of FULV and AZD-9496 (Fig. 5, Table S3). FULV’s tail establishes again hydrophobic interactions with 
L536 (Fig. S14).
Remarkably, in the crystal structures of the agonist EST/WT form, a fragment of the coactivator protein was 
crystallized in the groove between H3 and H5 (PDB ids: 3uud21, 4zn927, and 5jmm). In this structure, E380 forms 
a salt bridge with K688 of the coactivator fragment. In the antagonist WT/END form, this groove is occupied by 
H12, while E380 H-bonds to H377, preventing the binding of a coactivator protein.
Here we find evidences that in END/D538G H12 assumes a partial agonist conformation, forming a cavity 
within the H3–H5 groove, which may allow the binding of the coactivator protein (Fig. S16). This important 
finding further explains the reduced sensitivity of D538G to END and remarks the importance of E380 as on/off 
switch element of ERα mediated signal transduction.
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The only available crystal structure of the receptor in the antagonist conformation and with one of the mutations 
studied is that of D538G mutant, where 4-hydroxy-tamoxifen is present in the binding site (PDB id: 4q5022). This 
structure, is, however, missing the L11-12 segment, hampering a detailed comparison with our results. The overall 
rigidity/stability of the receptor in the presence of all antagonists is high (over 95% of all structures, Table S1)
Figure 5. Interaction network of H12 with H5. In first, second, and third columns END-, AZD-9496-, and 
FULV-bound complexes are shown, respectively. WT (white) ERα and L536Q (dark red), D538G (turquoise), 
Y537S (green), and Y537N (orange) mERαs are shown from the top to the bottom row. FULV in the third 
column is coloured in violet. H-bonds are shown as black dotted lines. Oxygen, nitrogen, and hydrogen 
atoms are coloured in red, blue, and white, respectively. The structures depict the highest populated clusters of 
monomer A, as obtained from the cluster analysis (Table S1).
www.nature.com/scientificreports/
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The Y537S Isoform. The correlation contacts of both monomers become very intense in Y537S/END (Fig. S12), 
while their intensity decreases and completely vanishes for Y537S/AZD-9496 and FULV, respectively. This is con-
sistent with the proved efficacy of both drugs18. Upon END binding H12 displays the largest degree of correlation 
with H3 and H5 in monomer A and H5 in monomer B (Fig. 4), suggesting that END can only poorly counteract 
the intrinsic activation of the receptor. FUL and AZD-9496 eliminate this correlation contact, restoring a stable 
antagonist state.
The high degree of correlation between H12 and H5 observed for END/Y537S is accounted by the persis-
tent H-bonds between E380 and both, the side chain and the backbone of S537. Their persistence is reduced by 
AZD-9496 (Table S3), which forms an extended network of H-bonds with the residues of L11-12, including S537 
(Tables S4 and S5). Besides establishing hydrophobic interactions with the L536 pocket, FULV also H-bonds with 
the residues at the edge of H12 (533–536), resulting in reduced E380 H-bonding with the S537 side chain, thus 
decreasing the formation of this activation structural trait in both monomers (Table S3, Fig. 5 and S14).
The cluster analysis (Table S1) reveals that AZD-9496 is the SERD stabilize/rigidify the antagonist conforma-
tion the most in both monomers, followed by END and FULV, which both stabilize/rigidify the structure only in 
monomer B.
The Y537N Isoform. Y357N, the second most aggressive mutant among those investigated here, induces 
H12-H5 correlation contact only for monomer A in the presence of all considered drugs (Fig. S13), however, the 
correlation score remains at the edge of the selected aggressive activation threshold (Fig. 4). Only FULV reduces 
the correlation score below 4 in both monomers. In this mutant, the persistence of the H-bond between E380 and 
H377 is very low, while that between E380 side chain and N537 backbone and side chain is high. This structural 
signature is invariant even in the presence of drugs (Table S3): AZD-9496 forms a H-bond network up to residue 
532 (Tables S4 and S5), while the interaction network of FULV is slightly more extended and complemented by 
hydrophobic interactions with L536.
Similarly, to Y537S, AZD-9496 is again the SERD stabilizing the most the antagonist conformation in both 
monomers (Table S1).
Ligand-receptor interactions: Implications for drug-design. All ligands occupy the active site in a similar manner, 
namely their heterocyclic rings have an orientation similar to that of EST. However, having distinct sizes, their 
tails interact differently with the receptor, especially in the L11-12 segment. In order to identify the subtle struc-
tural determinants allowing to rationalize the drug efficacy/inefficacy profile observed experimentally18, we have 
analysed the H-bonds and the hydrophobic interactions between the ligands and ERα as well as ligands’ stability 
within the binding pocket (Fig. S14).
Besides the interactions that the ligands establish with the binding pocket, AZD-9496 and FULV H-bond 
with the residues located in L11-12 (i. e. a salt bridge between carboxylic group of the ligand and K529 side chain 
in both monomers of WT, Y537S, and D538G in one monomer of L536Q), with the highest persistence being 
observed for D538G. This prevents H12 to interact with H5 and, in turn, to assume an agonist-like conformation.
In Y537S, the carboxylic group of AZD-9496 H-bonds with L536, C530, and with both, S537 backbone and 
side chain (Table S4), rationalizing AZD-9496 efficacy on Y537S. FULV, instead, persistently H-bonds with the 
backbone of L536. In all other isoforms, this H-bond is prevented, and FULV is mainly stabilized by hydrophobic 
interactions (Fig. S14), as shown by non-bonded interaction energies between the drug and the L11-12 and H12 
(Table S6).
In summary, AZD-9496 and FULV, due to their elongated shape, can form either H-bonds (mostly with K529 
and K531) or hydrophobic interactions with residues of L11-12 and H12, hampering H12 from establishing a cor-
relation contact with H5, and reducing the degree of ERα activation. As such, the direct interaction of the ligand 
with the L11-12 and, in particular, with the residues in the region 529–537, is crucial to exert an antagonistic/
downregulator activity even in aggressive polymorphisms. This appears to be in line with recently identified ERα 
downregulators, which bear a carboxyl moiety pointing towards L11-1229 and with the hydrophobic interactions 
with L536 observed for a potent antagonist with a new scaffold30.
In consequence, we expect that all drugs exhibiting efficacy against these aggressive mutants should carry 
H-bond-forming moieties up to the region 529–537, thus hampering the selection of an agonist-like conforma-
tional state in these polymorphisms (Fig. S17).
Summary and Conclusions. Understanding at atomistic level of detail how aggressive polymorphic vari-
ants of ERα trigger intrinsic ERα activation, along with the structural traits responsible for the improved efficacy 
profile of clinically used SERDs against these variants, is a prerequisite for personalized therapies to treat meta-
static BC patients relapsing fist-line endocrine treatments.
In this study, we performed cumulative 12.5 µs (i. e. 500 ns for each investigated system) classical MD simu-
lations to picture the complex conformational landscape of recurrent and aggressive pro-oncogenic mutations 
showing that: (i) all investigated apo ERα isoforms (L536Q, Y537S, Y537N, D538G), are constitutively active, 
explaining why these variants are refractory to therapies based on HA inhibitors. Nevertheless, our study strik-
ingly reveals that each isoform possesses a unique activation mechanism. Namely, when the polymorphism 
occurs at position 537, direct H-bonds are engaged between H12 and N348 and/or D351, making these mutants 
the most aggressive. In contrast, in L536Q and D538G, the mutations induce an overall disorder in the secondary 
structure at the edge of H12 and a decrease of its helical content; (ii) When introducing the polymorphic variants 
in the ERα antagonist state, a shift toward an agonist-like conformation occurs due to a structural rearrangement 
of L11-12 and to the formation of H-bonds between the mutated residues belonging to H12 and E380.
www.nature.com/scientificreports/
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This structural transition is crucial for ERα activation, even in the presence of END, and it is partially ham-
pered by the two SERDs computationally assayed here. Our study remarks the importance of E380 to regulate 
ERα activation mechanism, as confirmed by genomic studies31. (iii) The efficacy of AZD-9496 toward all ERα iso-
forms investigated may be attributed to a specific set of H-bonds that this drug establishes with the residues of the 
L11-12, mainly with K529/531. This H-bond network prevents the conformational transition of H12 towards the 
agonist-like state; (iv) The long FULV hydrophobic tail establishes hydrophobic interactions with L11-12 and H12 
(Table S6), which again impedes the shift towards an agonist-like ERα active conformation. (v) Finally, D538G/
END induces the conformational selection of a H12 state, creating a cavity able to bind a co-activator peptide. 
This suggests a potential alternative mechanism of counteracting the activity of this mutant.
As a note of warning, we remark that the length of our MD simulations is sufficient to explore the potential 
energy surface nearby the starting configuration. Large conformational changes, occurring on multiple micro-
seconds/millisecond time-scale induced by the mutants or the drugs, will not be fully captured here. Since ESR1 
mutations in metastatic BCs are highly recurrent, a detailed atomistic understanding of the structural traits 
needed by efficacious drugs can lead research efforts to identify more effective ERα antagonists/downregulators. 
Furthermore, our computational assay, providing for the first time a rational understanding of efficacy of drugs in 
(pre-)clinical use for each ERα isoform, can lead physicians to devise optimal personally tuned therapies on the 
basis of patients’ genetic profile.
Computational Methods. ERα models. The WT model was built starting from the crystal structure of 
17-β-estradiol (EST)-bound ERα dimer (PDB id: 1qku26). The apo form model was generated by removing EST 
from the binding site.
The antagonist adducts between END/AZD-9496 and WT ERα were built from the crystal structures 
of ERα monomer in complex with 4-hydroxy-tamoxifen and AZD-9496 (PDB ids: 3ert32 and 5acc19, respec-
tively). To generate END from the crystal structure, we deleted one of the two terminal methylene groups of 
4-hydroxy-tamoxifen. Then, we built the LDB dimer in the antagonist state by superimposing monomeric antag-
onist ERαs structures, solved by X-ray crystallography (PDB ids: 3ert32 or 5acc19), on the both monomers of the 
antagonist ERα crystal structure (PDB id: 1qku26). Since the agonist and antagonist structures differ only in the 
orientation of the H12, we expect the overall folding of the LDB monomers to be quite similar. Nonetheless, 
we verified the stability of the built dimers during the MD simulations (Fig. S3). The residues missing in the 
crystal structure of AZD-9496/ERα adduct (PBD id: 5acc19) were modelled according to the crystal structure of 
4-hydroxy-tamoxifen-bound ERα.
The crystal structure of FULV-bound ERα has not been solved, thus we built this model by removing 
4-hydroxy-tamoxifen from the crystal structure of antagonist ERα, and docking FULV in the binding site with 
the Glide software33,34. mERα models of all the antagonists and agonists adducts were built by making point 
mutations L536Q, Y537S, Y537N and D538G on the models with the Rotamers tool of UCSF Chimera35. This is 
based on the Dunbrack backbone-dependent rotamer library36. In total, we constructed 25 systems. Protonation 
states of ionisable residues have been determined according to H++ server37.
Molecular Dynamics (MD) Simulations. Each model was solvated with TIP3P water molecules in the truncated 
octahedron shaped box with the dimensions of at least 14 Å in each direction from the solute. In all simulations 
we used Amber99SB force field for protein38. Na+ ions were added to achieve system neutrality. Systems of agonist 
and antagonist adducts are composed by 81000 and 106000 atoms, respectively. The partial charges of each ligand 
were obtained by performing population analysis according to the Merz-Kollman scheme on the geometry opti-
mized structures at Hartree-Fock level with 6–31 G* basis set with the Gaussian0939. RESP charges were the gen-
erated with the Antechamber module of Amber1340. The other ligands force field parameters were obtained with 
Antechamber module, using as input bond lengths and bond angles obtained from the optimized geometries.
Prior to the production MD simulations, all systems were heated to the final temperature of 310 K using 40 
steps of simulated annealing (0–90 K in steps of 5 K/25 ps; 90–310 K in steps of 10 K/25 ps). Production runs 
were done with periodic boundary conditions at 310 K and 1 bar by coupling to the Nose-Hoover thermostat41,42 
and Parrinello-Rahman barostat43. Electrostatic interactions were taken into account using particle mesh Ewald 
method44. A time step of 2 fs was used, constraining bond lengths with the LINCS algorithm45. 500 ns long sim-
ulations were performed for each system and last 300 ns were considered for further analysis. Simulations were 
performed using Gromacs5.1.2 code46.
Analysis. The root mean square displacement (RMSD) and root mean square fluctuation (RMSF) were calcu-
lated with gmx_rms and gmx_rmsf modules of Gromacs 5.1.2, respectively. Trajectories were clustered using 
gmx_cluster module of Gromacs 5.1.2 according to their RMSD value using the clustering method reported by 
Daura et al.47. The selected RMSD cut-off value for clustering analysis was 2.75 Å.
The cpptraj module of Amber program was used for hydrogen bond analysis (cut-off parameters for 
H-bond was 3.3 Å and 35°), cross-correlation matrices, and analysis of the secondary structure48. For details on 
cross-correlation matrices calculations see Paragraph S2.
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